Literature DB >> 19067470

Diclofenac epolamine (Flector) patch: evidence for topical activity.

Birte Petersen1, Stefano Rovati.   

Abstract

This review focuses on previously unpublished clinical and pharmacokinetic data with the diclofenac epolamine (diclofenac hydroxyethylpyrrolidine) patch supporting the hypothesis of a topical effect of this formulation. Previous studies have shown that 1 or 2 weeks of treatment with diclofenac epolamine provides pain relief for various localized musculoskeletal conditions such as ankle sprains, epicondylitis and knee osteoarthritis. The reduction in pain after application of the first patch in 155 patients with painful knee osteoarthritis was significant at the 1-hour time point and was superior to placebo at the 3-hour time point and at all time points thereafter. Comparable results were found in a study of 274 patients with acute ankle sprains, in which pain relief was also significantly superior to placebo at the 3-hour time point. Corresponding single-dose (patch) application for 12 hours in ten healthy volunteers demonstrated that diclofenac first appears in plasma at a mean of 4.5 hours after application (range 2-8 hours). Hence, the patch provided pain relief at a time point at which no diclofenac is assumed to be in plasma, which demonstrates local action in terms of tissue diclofenac accumulation under the patch. This is further supported by an apparent plasma diclofenac half-life of 9-12 hours after patch application, which implies the presence of a tissue reservoir, as the half-life after oral intake of diclofenac is 1-2 hours.Steady-state plasma diclofenac concentrations are present before 3 days' application (two patches/day) and are in the order of 1-3 ng/mL. The bioavailability in terms of systemic exposure from the patch compared with oral intake (75 mg/day) is in the order of 1%. Such low diclofenac concentrations are without systemic effects, as demonstrated by the fact that no drug-related gastrointestinal bleeding, ulcers or cutaneous events characteristic of Steven-Johnson syndrome have been reported during 15 years of diclofenac epolamine patch use.These data provide support for the notion that diclofenac epolamine patch provides pain relief through accumulation of diclofenac under the site of application, without any evidence of systemic effects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19067470     DOI: 10.2165/0044011-200929010-00001

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  24 in total

1.  Intra-articular absorption and distribution of ketoprofen after topical plaster application and oral intake in 100 patients undergoing knee arthroscopy.

Authors:  C Rolf; B Engström; C Beauchard; L D Jacobs; A Le Liboux
Journal:  Rheumatology (Oxford)       Date:  1999-06       Impact factor: 7.580

Review 2.  Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls.

Authors:  N M Davies; K E Anderson
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

3.  Local tolerability and pharmacokinetic profile of a new transdermal delivery system, diclofenac hydroxyethylpyrrolidine plaster.

Authors:  A Assandri; S Canali; C Giachetti
Journal:  Drugs Exp Clin Res       Date:  1993

4.  Comparison of tissue and plasma levels of ibuprofen after oral and topical administration.

Authors:  M Dominkus; M Nicolakis; R Kotz; F E Wilkinson; R R Kaiser; K Chlud
Journal:  Arzneimittelforschung       Date:  1996-12

5.  Favourable dermal penetration of diclofenac after administration to the skin using a novel spray gel formulation.

Authors:  Martin Brunner; Pejman Dehghanyar; Bernd Seigfried; Wolfgang Martin; Georg Menke; Markus Müller
Journal:  Br J Clin Pharmacol       Date:  2005-11       Impact factor: 4.335

6.  Relief of acute low back pain with diclofenac-K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo-controlled clinical trial.

Authors:  R L Dreiser; M Marty; E Ionescu; M Gold; J H Liu
Journal:  Int J Clin Pharmacol Ther       Date:  2003-09       Impact factor: 1.366

Review 7.  OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines.

Authors:  W Zhang; R W Moskowitz; G Nuki; S Abramson; R D Altman; N Arden; S Bierma-Zeinstra; K D Brandt; P Croft; M Doherty; M Dougados; M Hochberg; D J Hunter; K Kwoh; L S Lohmander; P Tugwell
Journal:  Osteoarthritis Cartilage       Date:  2008-02       Impact factor: 6.576

8.  Peripheral and central antihyperalgesic effects of diclofenac in a model of human inflammatory pain.

Authors:  Maria Burian; Irmgard Tegeder; Maic Seegel; Gerd Geisslinger
Journal:  Clin Pharmacol Ther       Date:  2003-08       Impact factor: 6.875

9.  Pharmacokinetics of diclofenac hydroxyethylpyrrolidine (DHEP) plasters in patients with monolateral knee joint effusion.

Authors:  G Gallacchi; R Marcolongo
Journal:  Drugs Exp Clin Res       Date:  1993

10.  Diclofenac/N-(2-hydroxyethyl)pyrrolidine: a new salt for an old drug.

Authors:  A Fini; G Fazio; I Rapaport
Journal:  Drugs Exp Clin Res       Date:  1993
View more
  11 in total

1.  Diclofenac epolamine plus heparin plaster versus diclofenac epolamine plaster in mild to moderate ankle sprain: a randomized, double-blind, parallel-group, placebo-controlled, multicentre, phase III trial.

Authors:  Cosimo Costantino; Jacek Kwarecki; Anatoly V Samokhin; Giuseppe Mautone; Stefano Rovati
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 2.  Adverse effects of topical nonsteroidal antiinflammatory drugs in older adults with osteoarthritis: a systematic literature review.

Authors:  Una E Makris; Minna J Kohler; Liana Fraenkel
Journal:  J Rheumatol       Date:  2010-04-01       Impact factor: 4.666

Review 3.  Topical diclofenac epolamine patch 1.3% for treatment of acute pain caused by soft tissue injury.

Authors:  B H McCarberg; C E Argoff
Journal:  Int J Clin Pract       Date:  2010-10       Impact factor: 2.503

4.  An exploratory microdialysis study investigating the effect of repeated application of a diclofenac epolamine medicated plaster on prostaglandin concentrations in skeletal muscle after standardized physical exercise.

Authors:  Angela Burian; Valeria Frangione; Stefano Rovati; Giuseppe Mautone; Chiara Leuratti; Angelo Vaccani; Richard Crevenna; Mohammad Keilani; Bernhard Burian; Martin Brunner; Markus Zeitlinger
Journal:  Br J Clin Pharmacol       Date:  2013-12       Impact factor: 4.335

5.  Skin permeability and pharmacokinetics of diclofenac epolamine administered by dermal patch in Yorkshire-Landrace pigs.

Authors:  Susanna Tse; Kendall D Powell; Stephen J Maclennan; Allan R Moorman; Craig Paterson; Rosonald R Bell
Journal:  J Pain Res       Date:  2012-10-23       Impact factor: 3.133

6.  Diclofenac epolamine topical patch relieves pain associated with ankle sprain.

Authors:  David R Lionberger; Eric Joussellin; Arturo Lanzarotti; Jillmarie Yanchick; Merrell Magelli
Journal:  J Pain Res       Date:  2011-03-07       Impact factor: 3.133

7.  Topical preparations for pain relief: efficacy and patient adherence.

Authors:  Liliana L Jorge; Caroline C Feres; Vitor Ep Teles
Journal:  J Pain Res       Date:  2010-12-20       Impact factor: 3.133

8.  Blockade of leukocyte haptokinesis and haptotaxis by ketoprofen, diclofenac and SC-560.

Authors:  Saulius Paskauskas; Audrius Parseliunas; Vachtang Kerkadze; Rainer Nobiling; Jan Schmidt; Eduard Ryschich
Journal:  BMC Immunol       Date:  2011-11-12       Impact factor: 3.615

Review 9.  Pooled analysis of clinical trial data evaluating the safety and effectiveness of diclofenac epolamine topical patch 1.3% for the treatment of acute ankle sprain.

Authors:  David R Lionberger; Eric Joussellin; Jillmarie Yanchick; Merrell Magelli; Arturo Lanzarotti
Journal:  Open Access J Sports Med       Date:  2011-07-14

Review 10.  Topical Diclofenac, an Efficacious Treatment for Osteoarthritis: A Narrative Review.

Authors:  Frédérique Bariguian Revel; Marina Fayet; Martina Hagen
Journal:  Rheumatol Ther       Date:  2020-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.